ESTRO 2025 - Abstract Book

S1381

Clinical - Lung

ESTRO 2025

Conclusion: LANSCLC patients eligible to tumor SBRT seem to benefit from this treatment, with longer PFS and a trend to longer OS. SBRT immunomodulatory effect, timing and regimen should be further evaluated.

Keywords: NSCLC, SBRT, Durvalumab

References: 1. Viani GA, Gouveia AG, Louie AV, Arcidiacono F, Simone CB II, Tsakiridis T, et al. Stereotactic ablative radiotherapy for locally advanced NSCLC: A systematic review and meta-analysis. Radiother Oncol. 2024;201:110439. doi:10.1016/j.radonc.2024.110439. 2. Allignet B, De Ruysscher D, Martel-Lafay I, Waissi W. SBRT in unresectable stage III NSCLC: A systematic review. Cancer Treat Rev. 2023;118:102573. doi:10.1016/j.ctrv.2023.102573. 3. Heinzerling JH, Pen OV, Robinson M, Foster R, Kelly B, Mileham KF, et al. Full-dose SBRT with mediastinal chemoradiation for locally advanced NSCLC: A phase 2 study and planning guide for LU-008 trial. Pract Radiat Oncol. 2023. doi:10.1016/j.prro.2023.04.014.